196 filings
6-K
THTX
Theratechnologies Inc.
10 May 24
Report on Voting Results
1:10pm
6-K
THTX
Theratechnologies Inc.
9 May 24
Theratechnologies Reports on its Annual Meeting of Shareholders
5:26pm
6-K
THTX
Theratechnologies Inc.
15 Apr 24
Notice of Annual Meeting of Shareholders
9:31am
6-K
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
6-K
THTX
Theratechnologies Inc.
10 Apr 24
Theratechnologies Reports Financial Results
8:16am
6-K
gdxif io4eq14rk8
5 Apr 24
Theratechnologies Appoints Elina Tea to its Board of Directors
12:57pm
6-K
3iq 5nq09
22 Mar 24
Theratechnologies Announces Update on its Preclinical Oncology Research Program
4:27pm
6-K
s6keak djjnkjzoizw
22 Mar 24
Theratechnologies Appoints Jordan Zwick to its Board of Directors
1:37pm
6-K
tc5zmhus sddti1e
21 Mar 24
Current report (foreign)
12:40pm
6-K
kyodfayn
29 Feb 24
Theratechnologies Announces the Resignation of One of Its
4:55pm
6-K
esvf agt8ukc
27 Feb 24
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular
8:37am
6-K
v7v6 35esqg
21 Feb 24
Theratechnologies Reports Financial Results
8:00am
6-K
9laqut 6a
15 Feb 24
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
8:36am
6-K
cbx932m t5
6 Feb 24
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial
2:29pm
6-K
2b58a63q 9fbd2
1 Feb 24
Material Change Report
11:50am
6-K
smzyh
24 Jan 24
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
1:52pm
6-K
zosiit b35qr686
23 Jan 24
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental
2:01pm
EFFECT
naq1i0 h280owq
4 Jan 24
Notice of effectiveness
12:15am
F-3/A
7gu6uyq
2 Jan 24
Shelf registration (foreign) (amended)
4:28pm